Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes

Type 2 diabetes mellitus (T2DM) is a chronic progressive metabolic disease that has become a growing health problem worldwide, and the dangers of hyperglycemia and its chronic complications have long been considered a goal of diabetes treatment. In recent years, tirzepatide has become the first dual...

Full description

Saved in:
Bibliographic Details
Published in:Journal of diabetes research 2023-04, Vol.2023, p.5891532-8
Main Authors: Ma, Zijun, Jin, Kaiqin, Yue, Mengmeng, Chen, Xin, Chen, Jun
Format: Article
Language:English
Subjects:
Alzheimer's disease
Antidiabetics
Blood pressure
Cholesterol
Chronic illnesses
Diabetes
Diabetes Mellitus, Type 2
Drug dosages
Gastric Inhibitory Polypeptide
Glucagon
Glucagon-Like Peptide-1 Receptor
Glucose
Hemoglobin
Humans
Hyperglycemia
Hypoglycemic Agents
Insulin resistance
Liver diseases
Metabolism
Mortality
Obesity
Overweight
Peptides
Review
Risk factors
Triglycerides
Weight control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Type 2 diabetes mellitus (T2DM) is a chronic progressive metabolic disease that has become a growing health problem worldwide, and the dangers of hyperglycemia and its chronic complications have long been considered a goal of diabetes treatment. In recent years, tirzepatide has become the first dual GIP/GLP-1R agonist approved for the treatment of diabetes mellitus in the United States as a new hypoglycemic medicine. Its hypoglycaemic and weight loss effects have been demonstrated in several large clinical trials, and there is also evidence that it has great potential for cardiovascular protection. In addition, the very concept of synthetic peptides opens up many unknown possibilities for tirzepatide. Ongoing trials (NCT04166773) and evidence suggest that it appears to be a promising drug in the areas of NAFLD, renal, and neuroprotection. Based on preclinical studies and clinical trials, the aim of this article is to discuss the latest clinical developments in tirzepatide, to focus on its differences with other incretin therapies, and to suggest future possibilities and mechanisms of tirzepatide therapy.
ISSN:2314-6745
2314-6753
DOI:10.1155/2023/5891532